By Fineline Cube CSPC Pharmaceutical Group Ltd. (HKG: 1093) presented Phase I clinical data for SYS 6043, a novel B7-H3-targeting antibody-drug conjugate (ADC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The investigational therapy demonstrated robust antitumor activity across multiple solid tumor types with a favorable safety profile.
Clinical Trial Design & Patient Population
| Parameter | Detail |
|---|---|
| Study ID | ChiCTR2400094683 |
| Design | Multicenter, open-label, single-arm Phase I/II |
| Location | China |
| Primary Endpoints | Safety, tolerability, pharmacokinetics, preliminary efficacy |
| Total Enrolled | 627 patients (as of March 31, 2026) |
| Tumor Types | Lung cancer, gynecological tumors, breast cancer, nasopharyngeal carcinoma |
Drug Profile & Engineering Features
- Target: B7-H3 (tumor-associated antigen overexpressed in multiple cancers)
- Payload: Topoisomerase I inhibitor
- Drug-to-Antibody Ratio (DAR): Approximately 6
- Linker: Cleavable design for controlled payload release
- Fc Engineering: Fcγ receptor effector-silencing to reduce off-target toxicity
- Mechanism: Enhanced tumor-specific delivery with reduced systemic exposure
Efficacy Results – 533 Efficacy-Evaluable Patients
| Endpoint | Result |
|---|---|
| Objective Response Rate (ORR) | 41.8% |
| Disease Control Rate (DCR) | 81.4% |
| Median Duration of Response (mDoR) | 6.9 months |
| Tumor Types with Activity | Broad activity across lung, gynecological, breast, and nasopharyngeal cancers |
Safety Profile
- Overall Tolerability: Generally well tolerated across dose cohorts
- Dose-Limiting Toxicities (DLTs): Only 2 reported (both in 10 mg/kg Q3W group)
- Grade 3 gastrointestinal disorder (n=1)
- Grade 4 febrile neutropenia (n=1)
- Therapeutic Index: Favorable safety-efficacy balance supports continued development
Strategic Outlook & Market Implications
- ADC Pipeline Expansion: Positions CSPC as an emerging player in the competitive ADC space
- Global Development Potential: Strong ASCO presentation may facilitate international partnerships
- Regulatory Pathway: Robust dataset from 627-patient study supports potential accelerated approval strategies
- Commercial Opportunity: Addresses unmet need in B7-H3-positive solid tumors with limited treatment options
- Competitive Landscape: Differentiated by high DAR, cleavable linker, and Fc-silencing technology
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for SYS 6043. Actual results may differ due to risks including trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech